Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Core Viewpoint - Xenon Pharmaceuticals Inc. has announced the pricing of an upsized underwritten public offering of 10,526,317 common shares at a price of $57.00 per share, along with pre-funded warrants to purchase up to 877,194 common shares, aiming to raise approximately $650.0 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering includes common shares priced at $57.00 each and pre-funded warrants at $56.9999 each [1]. - The offering is expected to close on or about March 12, 2026, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,710,526 common shares at the public offering price [1]. Group 2: Underwriters - J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers for the offering, with Baird serving as the lead manager [2]. Group 3: Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [7]. - The company's lead molecule, azetukalner, is in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression [7]. - Xenon is also developing a portfolio of potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 for potential pain treatment [7].